# KCSG HB23-04 (NCT06138769)

> Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06138769
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Asan Medical Center
- Conditions: Hepatocellular Carcinoma
- Interventions: Lenvatinib
- Enrollment: 50
- Primary outcome: Progression-free survival

## Indexed commentary on KCSG HB23-04 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=kcsg-hb23-04-nct06138769